Distinguished in Parkinson's Disease

Dr. Omid Omidvar

Neurology
Southland Neurologic Institute A Medical Corporation
3747 Worsham Ave, Suite 100, 
Long Beach, CA 
Offers Telehealth
Distinguished in Parkinson's Disease
Southland Neurologic Institute A Medical Corporation
3747 Worsham Ave, Suite 100, 
Long Beach, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Omid Omidvar is a Neurologist in Long Beach, California. Dr. Omidvar is rated as a Distinguished provider by MediFind in the treatment of Parkinson's Disease. His top areas of expertise are Stroke, Charles Bonnet Syndrome, Parkinson's Disease, and Movement Disorders.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 7 clinical trials in the study of Parkinson's Disease.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Hospital Affiliations
Memorialcare Long Beach Medical Center
Uci Health-Lakewood
Uci Health - Los Alamitos
University Of California Irvine Medical Center
West Anaheim Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

SOUTHLAND NEUROLOGIC INSTITUTE A MEDICAL CORPORATION
3747 Worsham Ave, Suite 100, Long Beach, CA 90808

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
Enrollment Status: Completed
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: LY3372993
Study Phase: Phase 1
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: CVN424
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: TAK-071
Study Phase: Phase 2
A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome
A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome
Enrollment Status: Terminated
Publish Date: November 27, 2023
Intervention Type: Drug, Biological
Study Drug: Flebogamma
Study Phase: Phase 2/Phase 3
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
Enrollment Status: Completed
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease
Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease
Enrollment Status: Completed
Publish Date: August 02, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off
Enrollment Status: Terminated
Publish Date: May 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 13 Less Clinical Trials

5 Total Publications

Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia.
Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia.
Journal: Journal of neurology
Published: August 29, 2022
Similar Doctors
Elite in Parkinson's Disease
Dr. Michele Tagliati
Neurology
Elite in Parkinson's Disease
Dr. Michele Tagliati
Neurology

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (21.9 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michele Tagliati is a Neurologist in West Hollywood, California. Dr. Tagliati is rated as an Elite provider by MediFind in the treatment of Parkinson's Disease. His top areas of expertise are Movement Disorders, Parkinson's Disease, Drug Induced Dyskinesia, Essential Tremor, and Deep Brain Stimulation.

Elite in Parkinson's Disease
Dr. Mark F. Lew
Neurology
Elite in Parkinson's Disease
Dr. Mark F. Lew
Neurology

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (16.6 miles away)
323-442-8444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Lew is a Neurologist in Los Angeles, California. Dr. Lew is rated as an Elite provider by MediFind in the treatment of Parkinson's Disease. His top areas of expertise are Movement Disorders, Parkinson's Disease, Drug Induced Dyskinesia, and Focal Dystonia.

Elite in Parkinson's Disease
Dr. Jeff M. Bronstein
Neurology
Elite in Parkinson's Disease
Dr. Jeff M. Bronstein
Neurology

The Regents Of The University Of California

300 Medical Plz, 
Los Angeles, CA 
 (23.8 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeff Bronstein is a Neurologist in Los Angeles, California. Dr. Bronstein is rated as a Distinguished provider by MediFind in the treatment of Parkinson's Disease. His top areas of expertise are Movement Disorders, Parkinson's Disease, Hepatocerebral Degeneration, Wilson Disease, and Deep Brain Stimulation.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Omidvar's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 142 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile